English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recurrent genomic abnormalities identified in AML improve prognostic stratification of patients with normal karyotype AML (NK-AML).1, 2 Retrospective studies show that mutations in FLT3, NPM1 and CEBPα are powerful tools to predict outcomes in younger and older patients with NK-AML.3, 4, 5 Limited data exist on the role of allogeneic hematopoietic cell transplant (HCT) in NK-AML patients with recurrent genomic abnormalities.6, 7, 8 In this retrospective cohort study, we evaluated the outcomes of patients with NK-AML transplanted at a single institution to determine whether the widespread implementation of molecular testing in NK-AML patients at the time of diagnosis has impacted the outcomes of patients who ultimately undergo allogeneic HCT.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile